CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst sentiment is moderately positive: Fourteen analysts give CG Oncology an average “Moderate Buy” rating, with 11 buys, two holds and one sell. The average 12-month price target is $83.18.
• The stock has risen sharply: CGON opened at $79.81, near its 52-week high of $80.97, compared with a 52-week low of $25.25.
• Quarterly results missed expectations: CG Oncology reported a loss of $0.90 per share versus the expected $0.66 loss, although revenue of $1.16 million exceeded estimates of $0.36 million. Directors have made mixed trades, including a $24.8 million purchase and recent insider sales.

Shares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $83.1818.

CGON has been the topic of several research reports. Truist Financial upped their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Piper Sandler lifted their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Wolfe Research started coverage on shares of CG Oncology in a research report on Tuesday, May 19th. They set a "peer perform" rating for the company. Wedbush raised their price target on shares of CG Oncology from $77.00 to $80.00 and gave the company an "outperform" rating in a research report on Monday, May 11th. Finally, Wall Street Zen cut shares of CG Oncology from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th.

Insider Transactions at CG Oncology

In related news, Director Brian Guan-Chyun Liu bought 371,085 shares of the business's stock in a transaction that occurred on Thursday, June 25th. The shares were bought at an average price of $66.87 per share, with a total value of $24,814,453.95. Following the completion of the transaction, the director directly owned 1,886,236 shares in the company, valued at approximately $126,132,601.32. This represents a 24.49% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Leonard E. Post sold 1,000 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $74.54, for a total value of $74,540.00. Following the completion of the sale, the director directly owned 1,000 shares of the company's stock, valued at $74,540. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 38,129 shares of company stock valued at $2,738,357 over the last ninety days. 4.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fiduciary Financial Advisors purchased a new position in shares of CG Oncology in the 2nd quarter worth approximately $28,000. NFSG Corp purchased a new stake in CG Oncology during the first quarter valued at about $34,000. Comerica Bank boosted its holdings in CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company's stock worth $43,000 after buying an additional 515 shares during the period. Fifth Third Bancorp bought a new position in shares of CG Oncology in the first quarter worth $74,000. Finally, KBC Group NV bought a new position in CG Oncology in the 1st quarter worth about $78,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

CG Oncology Stock Performance

Shares of CG Oncology stock opened at $79.81 on Friday. The stock has a market capitalization of $7.07 billion, a PE ratio of -29.67 and a beta of 0.23. CG Oncology has a 52 week low of $25.25 and a 52 week high of $80.97. The stock has a 50 day moving average price of $71.31 and a two-hundred day moving average price of $65.54.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.24). CG Oncology had a negative return on equity of 25.20% and a negative net margin of 3,602.68%.The firm had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.36 million. Research analysts forecast that CG Oncology will post -3.27 EPS for the current year.

CG Oncology Company Profile

CG Oncology, Inc NASDAQ: CGON is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source